跳至主要内容
临床试验/CTRI/2020/12/030154
CTRI/2020/12/030154招募中1 期

A Prospective, Multi-Centre, First-In-Man, Pilot Clinical Investigation To Evaluate The Safety And Performance Of The FreedomÃ?® Total Knee System With The PEEK-OPTIMA Femoral Component - PEEK-OPTIMAââ??¢ FEMUR-01

Meril Life Sciences India Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
1 期
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Male and female subjects aged 50 years of age or older and less than 75 years of age ( >50 and
  • <75 years)
  • 2.Subjects who require uni-lateral knee prosthesis and have been evaluated as appropriate candidates for a total knee arthroplasty by the Investigator.
  • 3.Subjects with a primary diagnosis of end-stage symptomatic primary knee osteoarthritis.
  • 4.Subjects with the deformity of Varus with the anatomical limb alignment of 0-20 degrees
  • 5.Subjects who already have TKR done in other knee with a standard implant (must be compatible for the MRI evaluation as per the MRI protocol of the current study)
  • 6.Subjects, who in the opinion of the Investigator, are able to understand this clinical investigation, co-operate with the investigational procedures and are willing to return to the hospital for all the required post-operative follow-up.
  • 7.Subjects who are able to give voluntary, written informed consent to participate in this clinical investigation and from whom consent has been obtained.

排除标准

  • 1.Subjects who, in the opinion of the Investigator, have an existing condition that would compromise their participation and follow-up in this clinical investigation.
  • 2.Subjects who are known drug or alcohol abusers or with psychological disorders that could affect follow-up care or treatment outcomes.
  • 3.Subjects who have participated in a clinical study with an investigational product in the last 6 months.
  • 4. Subjects with other significant disabling problems from the muscular- skeletal system other than in the knees (i.e. muscular dystrophy, polio, neuropathic joints).
  • 5.Subject with the known osteoporosis (BMD T-Score below -2.5 and/or previous history of fracture related to osteoporosis. (severe osteoporosis as per WHO definition)
  • 6.Subjects with a Body Mass Index (BMI) of 32 or above.
  • 7.Subjects with a current or active history of malignancy, active or suspected infection, Pagetââ?¬•s disease, renal osteodystrophy, immunologically suppressed, rheumatoid arthritis, sickle cell anemia, and systemic lupus erythematosus.
  • 8. Subjects who have a neuromuscular or neurosensory deficit. Female subjects who are pregnant or lactating.
  • 9.Subjects with primary or secondary diagnosis of inflammatory or traumatic arthritis.ââ?°Â¥
  • 10.Subjects with a fixed flexion deformity of over 20 degrees.
  • 11.Subjects with recurvatum (definition: hyperextension ââ?°Â¥5 degrees
  • 12.Subjects who have previously undergone total or unicondylar knee arthroplasty, high tibial osteotomy, ligament reconstruction, open reduction and internal fixation (ORIF) or with previous fracture in the ipsilateral knee joint.

研究者

发起方
Meril Life Sciences India Pvt Ltd

相似试验